ATNM | Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Downgraded to Sell at Zacks Investment Research

Zacks Investment Research lowered shares of Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) from a hold rating to a sell rating in a research report released on Monday, reports.According to Zacks, “Actinium Pharmaceuticals, a clinical-stage biopharmaceutical company developing ARCs or Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of […]Daily Political